MedTrace Logo

Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA

NCT00843284 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 691

Last updated 2021-02-10

Study results available
· View outcomes & findings →

Summary

A Non-Interventional, Post-Marketing Surveillance (NI-PMS) study whose objectives were to assess the impact of pregabalin on subjects' pain, quality of sleep, and their general wellbeing, as well as the tolerance and safety of pregabalin in subjects with neuropathic pain.

Conditions

  • Neuropathic Pain

Interventions

DRUG

Pregabalin

Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-03-31
Completion
2008-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00843284 on ClinicalTrials.gov